Compare Mesoblast Limited (MESO) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Western Alliance Bancorporation — how do they compare? Mesoblast Limited trades at $14.29 (market cap $1.75B), while Western Alliance Bancorporation trades at $74.27 (market cap $8.24B). The key difference: Western Alliance Bancorporation is far larger — about 4.7× Mesoblast Limited's market cap, and Western Alliance Bancorporation pays a 2.23% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and Western Alliance Bancorporation for 3 Days on average.
| MESO | WAL | |
|---|---|---|
Market Cap | $1.75B | $8.24B |
Volume | 239,027 | 1,387,161 |
Sector | Health | Financials |
52-Week High | $20.96 | $96.08 |
52-Week Low | $13.19 | $66.70 |
Typical Hold Time | 15 Days | 3 Days |
Enterprise Value | $1.83B | $9.76B |
Dividend Yield | — | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $14.29, up 2.51% today, amid bearish technical signals but positive fundamental developments. The stock shows strong revenue growth with FY2026 reaching $120 million, though profitability remains negative. Recent FDA approval for Ryoncil's potency assay and completion of Phase 3 back pain trials provide catalysts. Technical indicators show oversold conditions with RSI at 22.4, while moving averages signal bearish momentum.
Investment outlook balances high growth potential against persistent losses. The expanding Ryoncil market share and pipeline progress offer upside, but negative margins and cash burn pose risks. Analyst consensus leans bullish with 45% buy ratings, yet the stock faces execution challenges in achieving profitability amid competitive pressures.
Western Alliance Bancorporation (WAL) trades at $74.27, down 0.11% with a bearish technical signal. The stock shows strong fundamentals with a P/E of 8.52 and net income margin of 25.43%, while recent earnings beat expectations in two of the last three quarters. Analyst consensus remains strongly bullish with a $84.33 price target, supported by institutional buying activity and positive business developments including the launch of WA VenueX platform.
WAL presents a compelling value opportunity with attractive valuation metrics and solid profitability, though technical indicators suggest near-term weakness. Key risks include regulatory changes affecting banking thresholds and potential margin pressure from interest rate environment. The stock's 13.43% ROE and 79% analyst buy rating support long-term upside potential above current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
